Drugs / A244
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04658667 | Feb 2022 → Jul 2024 | HIV infectious disease | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05423418 Comparator | Sep 2022 → Oct 2024 | AIDS | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | A244 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05423418 ↗ |
| Modality | Vaccine | “candidate vaccine A244/B.63521” NCT05423418 ↗ |
| Route | Intramuscular | “Participants will receive 2 intramuscular (IM) injections into the quadriceps muscle at Day 0.” NCT04658667 ↗ |